×

Compositions and methods to enhance the immune system

  • US 9,352,037 B2
  • Filed: 01/13/2014
  • Issued: 05/31/2016
  • Est. Priority Date: 04/23/2008
  • Status: Active Grant
First Claim
Patent Images

1. A composition comprising(i) a therapeutic compound that can trigger a host'"'"'s immune effector cells against a cancer cell, wherein said therapeutic compound is a therapeutic antibody comprising a human or non-human primate IgG Fc portion, wherein the therapeutic antibody induces antibody-dependent cellular cytotoxicity (ADCC), and wherein the therapeutic antibody is selected from the group consisting of rituximab, herceptin, trastuzumab, alemtuzumab, bevacizumab, cetuximab and panitumumab, and(ii) at least one agent capable of reducing or preventing inhibitory signal transduction initiated via SIRPα

  • , wherein said agent is an anti-CD47 antibody or an anti-SIRPα

    antibody or a Fab fragment, a F(ab′

    )2 fragment or a scFv fragment thereof.

View all claims
  • 1 Assignment
Timeline View
Assignment View
    ×
    ×